drugset / Trial / NCT03308825
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The aim of the study was to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone Quadrivalent vaccine in children 6 months to \< 9 years of age, and in adults 18 to \< 65 years of age, and to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone High-Dose vaccine in adults ≥ 65 years of age.
Timeline
- Start
- 2017-09-11
- Primary completion
- 2017-11-22
- Completion
- 2017-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzone High-Dose vaccine | Vaccine | 0.5 ml | Intramuscular |
| Subject | Fluzone Quadrivalent vaccine | Vaccine | 0.25 ml | Intramuscular |
| Subject | Fluzone Quadrivalent vaccine | Vaccine | 0.5 ml | Intramuscular |